Locomotor Recovery and Compensation Post-stroke (LRC) (LRC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Recovery of locomotion is a primary goal of rehabilitation post-stroke and a major determinant of future morbidity and mortality. While substantial recovery is observed early post-stroke, recent evidence suggests the magnitude and time course of recovery is deterministic and based primarily on initial motor deficits. The "proportional recovery" rule suggests ~70% of neurological recovery (measured by the lower limb Fugl-Meyer Assessment - LL-FMA) is typically achieved and is not influenced by the dosage of therapy. These findings suggest the physical interventions applied to patients are of minimal importance to long-term recovery. That hypothesis conflicts directly with our recent efforts suggesting that maximizing the amount and intensity of task-specific (stepping) practice (high-intensity training; HIT) directly influences gains in locomotor function. Providing HIT at heart rates (HRs) greater than traditional aerobic paradigms (mean 110% baseline HRmax) is associated with gains in locomotor speed, which challenges the notion of "proportional recovery".
These conflicting hypotheses likely arise from differences in terminology and methodology used to characterize recovery post-stroke. First, the traditional measure of neurological recovery (LL-FMA) does not adequately characterize other impairments (strength, postural stability) that are more closely associated to locomotor function and are responsive to physical interventions. Second, despite gains in selected impairments, patients often utilize alternative (compensatory) movement patterns to accomplish locomotor tasks. More directly, locomotor recovery (i.e., speed/distance) is often accomplished using strategies employed prior to stroke and compensatory strategies, particularly in those with substantial impairments.
Our central hypothesis is that if changes in neurological recovery are deterministic, other measures of locomotor recovery or compensations may also be predictable. Our published data detail how HIT or conventional interventions can alter impairments and locomotor recovery, as well as changes in locomotor compensations. More directly, our data provide evidence that specific subgroups of patients demonstrate substantial compensations with improved recovery, whereas others reveal limited changes despite similar interventions. Data that detail the progression of neurological recovery, locomotor recovery, and locomotor compensations throughout the subacute to chronic phase post-stroke and their responsiveness to HIT is uncertain. Similar to upper limb recovery algorithms, predictions of mobility outcomes could provide valuable information to clinicians who make decisions regarding patient's prognosis, including whether patients will be able to walk with or without assistance or at certain speeds, and what compensatory strategies they may require to ambulate independently (braces, devices or altered movement patterns). The overarching goal of this project is to examine the time course of neurological and locomotor recovery, and associated compensatory strategies, over the subacute to chronic stages post-stroke and their responsiveness to HIT.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Thomas G Hornby
- Phone Number: 3173292353
- Email: tghornby@Iu.edu
Study Contact Backup
- Name: Chris Henderson
- Phone Number: 3173292353
- Email: henderce@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46254
- Recruiting
- Rehabilitation Hospital of Indiana
-
Contact:
- Thomas G Hornby
- Phone Number: 312-350-8291
- Email: tghornby@Iu.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- individuals early post-stroke (<15-30 days)
- first ever stroke
- unilateral hemiparesis
- currently receiving inpatient rehabilitation
- ability to follow 1-step commands
- provision of informed consent
- medical clearance from the rehabilitation physician to participate. \
Exclusion criteria:
- uncontrolled cardiovascular, metabolic or respiratory disease that limits exercise participation (e.g., congestive heart failure, resting blood pressure > 200/110 mmHg, uncontrolled diabetes, end-stage renal disease)
- absolute criteria for termination of exercise testing during initial and repeated ECG testing during graded exercise testing using ACSM guidelines .
- other orthopedic or neurological disorder that limited walking prior to stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Phase 1
Observational evaluations for 6 months followed by 3-4 months of high-intensity training (HIT)
|
Approximately 10 weeks (~30 sessions) of high-intensity training
Other Names:
|
|
Other: Phase 2
Observational evaluations for 1 month followed by 3-4 months of high-intensity training (HIT)
|
Approximately 10 weeks (~30 sessions) of high-intensity training
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gait speed
Time Frame: 15 days post-stroke
|
Walking speed over 6 m
|
15 days post-stroke
|
|
Gait speed
Time Frame: 1 month
|
Walking speed over 6 m
|
1 month
|
|
Gait speed
Time Frame: 2 months,
|
Walking speed over 6 m
|
2 months,
|
|
Gait speed
Time Frame: 4 months,
|
Walking speed over 6 m
|
4 months,
|
|
Gait speed
Time Frame: 6 months,
|
Walking speed over 6 m
|
6 months,
|
|
Gait speed
Time Frame: 9 months,
|
Walking speed over 6 m
|
9 months,
|
|
Gait speed
Time Frame: 12 months
|
Walking speed over 6 m
|
12 months
|
|
Walking distance
Time Frame: 15 days post-stroke,
|
Distance covered over 6 min
|
15 days post-stroke,
|
|
Walking distance
Time Frame: 1 month,
|
Distance covered over 6 min
|
1 month,
|
|
Walking distance
Time Frame: 2 months,
|
Distance covered over 6 min
|
2 months,
|
|
Walking distance
Time Frame: 4 months,
|
Distance covered over 6 min
|
4 months,
|
|
Walking distance
Time Frame: 6 months,
|
Distance covered over 6 min
|
6 months,
|
|
Walking distance
Time Frame: 9 months,
|
Distance covered over 6 min
|
9 months,
|
|
Walking distance
Time Frame: 12 months
|
Distance covered over 6 min
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
peak knee angle
Time Frame: 6 months
|
peak knee angle during swing phase
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thomas G Hornby, Indiana University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IU2011618233
- 1R01NS118009 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.